[Gastrointestinal cytomegalovirus infections in organ transplant patients]

Area of Science:

• Gastroenterology
• Virology
• Transplant Medicine

Background:

• Cytomegalovirus (CMV) is a significant opportunistic pathogen in immunocompromised individuals, particularly organ transplant recipients.
• While 80-90% of transplant patients experience CMV infection, 30-40% develop CMV disease, with 10% specifically affecting the gastrointestinal tract.
• Gastrointestinal CMV disease presents with diverse pathologies including mucosal injury, ulcerations, hemorrhage, dysmotility, and rarely masses or perforations.

Purpose of the Study:

• To outline the diagnostic methods for gastrointestinal Cytomegalovirus disease.
• To describe the treatment and prevention strategies for gastrointestinal Cytomegalovirus disease in organ transplant patients.

Main Methods:

• Diagnosis relies on endoscopy with mucosal biopsies for histopathological examination, identifying characteristic cytomegalic cells with intranuclear ('owl's eye') and intracytoplasmic inclusions.
• Ancillary diagnostic methods include microbiological, immunohistochemical, and molecular assays to detect CMV in mucosal tissues.
• Treatment involves both gastroenterological management and antiviral therapy, primarily ganciclovir intravenously or valganciclovir orally.

Main Results:

• Histopathology of biopsy samples is crucial for diagnosing gastrointestinal CMV disease, revealing specific cytomegalic inclusions.
• Microbiological, immunohistochemical, and molecular assays can further confirm CMV presence in affected mucosa.
• Treatment necessitates a combination of gastroenterological care and antiviral agents like ganciclovir or valganciclovir.

Conclusions:

• Gastrointestinal Cytomegalovirus disease requires prompt diagnosis via endoscopy and biopsy, confirmed by characteristic histopathological findings.
• Effective management combines gastroenterological support with antiviral treatments such as ganciclovir or valganciclovir.
• Prevention strategies, including general prophylaxis with valganciclovir and preemptive therapy based on surveillance, are essential for high- and middle-risk transplant patients.